By


Combination of Checkpoint Inhibitors and Intezyne’s Novel Cancer Resistance Pathway Inhibitor IT-139 Shows Enhanced Immune Efficacy

 

See more here

By


Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer

See more here

By


IView Therapeutics was awarded SBIR Innovative grant by NIH’s National Institute of Allergy and Infectious Diseases (NIAID)

See more here

By


Data on Cancer Resistance Pathway Inhibitor IT-139 to be Presented at AACR 2018 Annual Meeting 

 

See more here

By


VenatoRx Pharmaceuticals to Present its Lead Clinical Antibacterial Candidate, VNRX-5133, at the American Chemical Society National Meeting

 

See more here

By


Intezyne Partners with Exosome Diagnostics on IT-139 Companion Diagnostic

 

See more here

By


Intezyne Taps Veteran Banker E. Russell McAllister  as President and CEO

 

See more here

By


Pillo Health and Orbita Partner to Deliver Engaging Voice-first Experiences via a First-of-its-kind Digital Care Management Platform for Home

 

See more here

By


Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System

See more here

By


BioAdvance Commits $3.2M to Life Sciences Companies in First Six Months of FY 2018
Investment Capabilities Expanded as Frederick (“Rick”) Jones, M.D., M.B.A., Joins Team 

See more here